Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydralazine and Valproate with Chemoradiation in Cervical Cancer
NCT00404326Phase 2Completed
- Sponsor
- Instituto Nacional de Cancerología
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydralazine and magnesium valproate in Cervical Cancer (CC), sponsored by Instituto Nacional de Cancerología. Primary endpoints: Clinical Complete Response Rate and Safety and Toxicity. Started May 2005; status: completed.
02
Drugs
hydralazinemagnesium valproate
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00404326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00404326.